A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day One Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal
cavity cancer

- Stage IIB, IIC, III, or IV disease

- Optimal or suboptimal residual disease after debulking surgery within the past
12 weeks

- Appropriate tissue for histologic evaluation available

- The following histologic epithelial cell types are eligible:

- Serous adenocarcinoma

- Endometrioid adenocarcinoma

- Mucinous adenocarcinoma

- Undifferentiated carcinoma

- Clear cell adenocarcinoma

- Mixed epithelial carcinoma

- Transitional cell carcinoma

- Malignant Brenner tumor

- Adenocarcinoma not otherwise specified

- Carcinosarcoma

- No ovarian epithelial carcinoma of low malignant potential (borderline carcinomas)

- No synchronous primary endometrial cancer or a history of primary endometrial cancer
unless all of the following conditions are met:

- Stage ≤ IB disease

- No more than superficial myometrial invasion, without vascular or lymphatic
invasion

- No poorly differentiated subtypes, including papillary serous, clear cell, or
other FIGO grade 3 lesion

PATIENT CHARACTERISTICS:

- GOG performance status 0-2

- ANC ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Serum creatinine ≤ 1.5 times upper limit of normal (ULN)

- Bilirubin ≤ 1.5 times ULN

- Alkaline phosphatase ≤ 2.5 times ULN

- SGOT ≤ 2.5 times ULN

- Audiograms required after study chemotherapy courses 3 and 6 for patients with
hearing loss, or who are experiencing tinnitus during study therapy

- Negative pregnancy test

- Not pregnant or nursing

- Fertile patients must use effective contraception

- None of the following:

- Septicemia

- Severe infection requiring parenteral antibiotics

- Malnutrition requiring parenteral hyperalimentation

- Acute hepatitis

- Any other major medical conditions expected to interfere with completion of
protocol therapy

- No active bleeding

- No circumstances that would prohibit completion of study therapy or required
follow-up

- No history of allergic reaction to polysorbate 80 (e.g., etoposide or vitamin E)

- No other invasive malignancies, except for nonmelanoma skin cancer or other specific
malignancies within the past 5 years, or whose previous cancer treatment
contraindicates this protocol therapy

- No unstable angina or myocardial infarction within the past 6 months

- Abnormal cardiac conduction (e.g., bundle branch block or heart block) that has
been stable for the past 6 months allowed

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior chemotherapy

- No prior radiotherapy

- No prior hormonal therapy for the management of epithelial ovarian or primary
peritoneal cavity cancer

- No prior targeted therapy for the management of ovarian epithelial or primary
peritoneal cavity cancer including, but not limited to, the following:

- Vaccines

- Antibodies

- Tyrosine kinase inhibitors